Cyclooxygenase 2: from inflammation to carcinogenesis
- PMID: 15027493
Cyclooxygenase 2: from inflammation to carcinogenesis
Abstract
Cyclooxygenase (COX) is the rate-limiting enzyme in the conversion of arachidonic acid to prostanoids. Two COX isoforms have been cloned, of which COX-1 is constitutively expressed, while the expression of COX-2 is low or nondetectable in most tissues, but can be readily induced in response to cell activation by cytokines, growth factors and tumour promoters. Thus, COX-1 is considered a housekeeping gene and thought to be responsible for the synthesis of prostanoids involved in cytoprotection of the stomach and for the production of the pro-aggregatory prostanoid thromboxane by the platelets. In contrast, COX-2 is an inducible, immediate-early gene, and its role has been related to inflammation, reproduction and carcinogenesis. Expression of COX-2 is elevated in a variety of human malignancies and in their precursor lesions. Furthermore, genetic deletion or pharmacological inhibition of COX-2 suppresses tumour growth in several animal models of carcinogenesis. In humans, elevated COX-2 expression is associated with poor prognosis in adenocarcinomas of the digestive tract and the breast, and a selective inhibitor of COX-2 reduced polyp burden in patients who suffer from familial adenomatous polyposis. Thus, COX-2 seems to be a relevant target in chemoprevention.
Similar articles
-
Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention.Biochem Pharmacol. 2004 Sep 15;68(6):1089-100. doi: 10.1016/j.bcp.2004.05.031. Biochem Pharmacol. 2004. PMID: 15313405 Review.
-
[Biological functions of cyclooxygenase 2: control of its expression and activity].J Soc Biol. 2000;194(3-4):189-93. J Soc Biol. 2000. PMID: 11324321 Review. French.
-
Cyclooxygenase-2 upregulation as a perigenetic change in carcinogenesis.J Exp Clin Cancer Res. 2001 Mar;20(1):117-29. J Exp Clin Cancer Res. 2001. PMID: 11370818 Review.
-
Cyclooxygenase-2 (COX-2) enzyme inhibitors and radiotherapy: preclinical basis.Am J Clin Oncol. 2003 Aug;26(4):S66-9. doi: 10.1097/01.COC.0000074160.49879.51. Am J Clin Oncol. 2003. PMID: 12902859 Review.
-
Hepatocellular carcinoma: is there a potential for chemoprevention using cyclooxygenase-2 inhibitors?Cancer. 2003 Aug 15;98(4):661-7. doi: 10.1002/cncr.11576. Cancer. 2003. PMID: 12910508 Review.
Cited by
-
Taxifolin attenuates inflammation via suppressing MAPK signal pathway in vitro and in silico analysis.Chin Herb Med. 2022 Sep 1;14(4):554-562. doi: 10.1016/j.chmed.2021.03.002. eCollection 2022 Oct. Chin Herb Med. 2022. PMID: 36405054 Free PMC article.
-
The Rho-activating CNF1 toxin from pathogenic E. coli: a risk factor for human cancer development?Infect Agent Cancer. 2008 Mar 12;3:4. doi: 10.1186/1750-9378-3-4. Infect Agent Cancer. 2008. PMID: 18336718 Free PMC article.
-
The cytotoxic necrotizing factor 1 from E. coli: a janus toxin playing with cancer regulators.Toxins (Basel). 2013 Aug 14;5(8):1462-74. doi: 10.3390/toxins5081462. Toxins (Basel). 2013. PMID: 23949007 Free PMC article. Review.
-
Multiple drug resistance-associated protein 4 (MRP4), prostaglandin transporter (PGT), and 15-hydroxyprostaglandin dehydrogenase (15-PGDH) as determinants of PGE2 levels in cancer.Prostaglandins Other Lipid Mediat. 2015 Jan-Mar;116-117:99-103. doi: 10.1016/j.prostaglandins.2014.11.003. Epub 2014 Nov 27. Prostaglandins Other Lipid Mediat. 2015. PMID: 25433169 Free PMC article. Review.
-
CD47 regulates collagen I-induced cyclooxygenase-2 expression and intestinal epithelial cell migration.PLoS One. 2009 Jul 28;4(7):e6371. doi: 10.1371/journal.pone.0006371. PLoS One. 2009. PMID: 19636412 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Research Materials